|Articles|September 1, 2004
- Pharmaceutical Executive-09-01-2004
September Table of Contents
September Table of Contents
Advertisement
Articles in this issue
almost 22 years ago
September Table of Contentsalmost 22 years ago
(Huge) Untapped Opportunityalmost 22 years ago
Information Into Actionalmost 22 years ago
Halting the Hypealmost 22 years ago
Spend Trends: A $20 Billion Bill and Plenty of Changealmost 22 years ago
From the Mouths of Babesalmost 22 years ago
Safe and Securealmost 22 years ago
Synta's Surprisealmost 22 years ago
The New Building Blocks for Blockbustersalmost 22 years ago
Specialty Therapies Lose Special StatusAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
5